8-K: Co-Diagnostics Reports First Quarter 2024 Financial Results with Increased Operating Loss

Co-Diagnostics reported a decrease in revenue and an increased net loss for the first quarter of 2024, alongside strategic expansions and leadership changes.

Summary

• Co-Diagnostics announced its financial results for the quarter ended March 31, 2024, revealing a revenue of $0.5 million, down from $0.6 million in the same period last year.
• The company experienced an operating loss of $10.3 million, compared to $10.0 million in the first quarter of 2023.
• Net loss for the quarter was $9.3 million, or $0.31 per fully diluted share, compared to a net loss of $5.8 million, or $0.20 per fully diluted share, in the prior year.
• Adjusted EBITDA loss was $8.4 million, compared to $7.2 million in the first quarter of 2023.
• The company's cash, cash equivalents, and marketable securities totaled $50.0 million as of March 31, 2024.
• Operating expenses increased by 4.4% year-over-year to $10.5 million, primarily due to increased research and development costs.
• The company inaugurated a new manufacturing facility in South Salt Lake and continued expansion of its facility in India.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to decreased revenue, increased losses, and increased operating expenses. However, the company is making strategic moves with new facilities and leadership, which provides some optimism.

Positives

• Co-Diagnostics has $50.0 million in cash, cash equivalents, and marketable securities.
• The company inaugurated a new manufacturing facility in South Salt Lake.
• Expansion of the CoSara manufacturing facility in India is underway.
• The company is progressing with the development of TB, multiplex respiratory, and HPV tests.
• New leadership appointments were made, including a new President, COO, CTO, and CCO.

Negatives

• Revenue decreased to $0.5 million from $0.6 million in the prior year.
• The net loss increased to $9.3 million from $5.8 million in the prior year.
• The loss per share increased to $0.31 from $0.20 in the prior year.
• Adjusted EBITDA loss increased to $8.4 million from $7.2 million in the prior year.
• Operating expenses increased by 4.4% year-over-year.

Risks

• The company's new PCR platform is subject to FDA review and is not yet available for sale.
• There is no guarantee that the anticipated results will occur on a timely basis or at all.
• The company's financial performance is subject to inherent uncertainties, risks, and changes in circumstances.
• The company's future success depends on the successful development and commercialization of its new products.

Future Outlook

Co-Diagnostics is committed to delivering a 510(k) submission to the FDA for its new instrument and COVID-19 test kit in the near future and plans to begin clinical evaluations for its multiplex test later this year. The company also plans to provide updates on its new platform and pipeline progress as they come.

Management Comments

• We are extremely encouraged by our first quarter progress and believe that we are well positioned to meet our 2024 goals, said Dwight Egan, Co-Diagnostics Chief Executive Officer.
• Co-Diagnostics was pleased to announce the opening of our new manufacturing facility in Salt Lake and continued facility expansion in India, which will soon enable in-house Co-Primers, instrument, and test manufacturing at a low cost.
• We remain committed to delivering a 510(k) submission to the FDA for our new instrument and COVID-19 test kit in the near future and driving development of our TB, multiplex respiratory, and HPV tests throughout the remainder of the year, said Brian Brown, Co-Diagnostics Chief Financial Officer.
• This is an exciting time for Co-Diagnostics and we truly believe in the disruptive and unique nature of our new platform.

Industry Context

The molecular diagnostics industry is highly competitive, with companies focused on developing and commercializing innovative testing solutions. Co-Diagnostics' efforts to expand manufacturing capabilities and develop new tests align with the industry's focus on improving diagnostic accuracy and accessibility. The company's focus on a new PCR platform and multiplex testing is in line with current trends in the industry.

Comparison to Industry Standards

• Compared to companies like QuidelOrtho, which reported Q1 2024 revenue of $745.8 million, Co-Diagnostics' revenue of $0.5 million is significantly lower, indicating a much smaller scale of operations.
• Companies like Exact Sciences, which reported a Q1 2024 net loss of $177.8 million, demonstrate that high R&D spending and losses are common in the diagnostic sector, but Co-Diagnostics' loss of $9.3 million is on a smaller scale.
• While companies like Bio-Rad Laboratories have a more diversified product portfolio and a larger revenue base, Co-Diagnostics is focused on its proprietary PCR platform, which is a different strategic approach.
• The expansion of manufacturing facilities by Co-Diagnostics is similar to moves by other diagnostic companies to control costs and improve supply chain efficiency, but the scale of Co-Diagnostics' expansion is smaller than that of larger players.

Management Changes

Stakeholder Impact

• Shareholders will be concerned about the increased losses and decreased revenue.
• Employees may be impacted by the company's strategic changes and expansion.
• Customers may benefit from the development of new diagnostic tests.
• Suppliers may see increased business due to the company's manufacturing expansion.
• Creditors will be monitoring the company's financial performance.

Next Steps

• The company plans to submit a 510(k) application to the FDA for its new instrument and COVID-19 test kit.
• Clinical evaluations for the multiplex test are planned for later this year.
• The company will provide updates on its new platform and pipeline progress as they come.

Key Dates

Keywords

molecular diagnostics, financial results, revenue, net loss, EBITDA, manufacturing, FDA, Co-Diagnostics, COVID-19, PCR, research and development